Morgensztern, D., Ready, N. E., Johnson, M. L., Dowlati, A., Choudhury, N. J., Carbone, D. P., … Furqan, M. (2023). First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Morgensztern, Daniel, Neal E. Ready, Melissa Lynne Johnson, Afshin Dowlati, Noura J. Choudhury, David Paul Carbone, Eric S. Schaefer, et al. “First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Morgensztern D, Ready NE, Johnson ML, Dowlati A, Choudhury NJ, Carbone DP, et al. First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Morgensztern, Daniel, et al. “First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Morgensztern D, Ready NE, Johnson ML, Dowlati A, Choudhury NJ, Carbone DP, Schaefer ES, Arnold SM, Puri S, Piotrowska Z, Hegde AM, Chiang AC, Iams WT, Tolcher AW, Nosaki K, Zha J, Li R, Hingorani P, Jeng EE, Furqan M. First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023.